Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$648K Buy
5,706
+130
+2% +$15.4K 0.15% 113
2024
Q2
$690K Buy
5,576
+30
+0.5% +$3.86K 0.16% 105
2024
Q1
$732K Buy
5,546
+43
+0.8% +$5.3K 0.18% 102
2023
Q4
$600K Sell
5,503
-208
-4% -$21.6K 0.16% 108
2023
Q3
$588K Buy
5,711
+3
+0.1% +$323 0.16% 109
2023
Q2
$659K Buy
5,708
+243
+4% +$27.6K 0.17% 111
2023
Q1
$581K Buy
5,465
+33
+0.6% +$3.56K 0.15% 117
2022
Q4
$603K Sell
5,432
-246
-4% -$25.1K 0.16% 117
2022
Q3
$489K Buy
+5,678
New +$507K 0.13% 121
2016
Q1
Sell
-738
Closed -$37K 212
2015
Q4
$37K Buy
+738
New +$37.2K 0.02% 169

Other funds holding MRK

Kingfisher Capital's MRK Position: Q3 2024 in Review

Kingfisher Capital increased its Merck (MRK) stake by 2.3% in Q3 2024, buying an estimated $15.4K and bringing the position to 5,706 shares worth $648K. The position accounts for 0.15% of the portfolio, ranked #113.

Kingfisher Capital first reported a position in MRK in Q4 2015 and has held it in 10 quarters since. The position peaked at $732K in Q1 2024. 3,489 funds tracked by Wall St. Rank hold MRK as of Q3 2024.

  • Kingfisher Capital held 5,706 shares of Merck worth $648K as of Q3 2024.
  • Kingfisher Capital bought 130 Merck shares in Q3 2024, an estimated $15.4K.
  • Merck made up 0.15% of Kingfisher Capital's portfolio in Q3 2024, its #113 holding.
  • Kingfisher Capital first reported a position in Merck in Q4 2015 and has held it in 10 quarters since.
  • Kingfisher Capital's Merck position peaked at $732K in Q1 2024.
  • 3,489 funds tracked by Wall St. Rank held Merck as of Q3 2024.

Based on Kingfisher Capital's 13F filing for Q3 2024, filed 14 Nov 2024.